148 related articles for article (PubMed ID: 2769668)
1. Urinary hydroxy-pyridinium crosslinks provide indices of cartilage and bone involvement in arthritic diseases.
Seibel MJ; Duncan A; Robins SP
J Rheumatol; 1989 Jul; 16(7):964-70. PubMed ID: 2769668
[TBL] [Abstract][Full Text] [Related]
2. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.
Garnero P; Gineyts E; Christgau S; Finck B; Delmas PD
Arthritis Rheum; 2002 Jan; 46(1):21-30. PubMed ID: 11817593
[TBL] [Abstract][Full Text] [Related]
3. Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: results of a pilot study.
Seibel MJ; Woitge H; Scheidt-Nave C; Leidig-Bruckner G; Duncan A; Nicol P; Ziegler R; Robins SP
J Bone Miner Res; 1994 Sep; 9(9):1433-40. PubMed ID: 7817828
[TBL] [Abstract][Full Text] [Related]
4. Levels of serum and synovial fluid pyridinium crosslinks in patients with rheumatoid arthritis.
Furumitsu Y; Inaba M; Yukioka K; Yukioka M; Kumeda Y; Azuma Y; Ohta T; Ochi T; Nishizawa Y; Morii H
J Rheumatol; 2000 Jan; 27(1):64-70. PubMed ID: 10648019
[TBL] [Abstract][Full Text] [Related]
5. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.
Charni N; Juillet F; Garnero P
Arthritis Rheum; 2005 Apr; 52(4):1081-90. PubMed ID: 15818703
[TBL] [Abstract][Full Text] [Related]
6. A cross sectional analysis of 5 different markers of collagen degradation in rheumatoid arthritis.
St Clair EW; Moak SA; Wilkinson WE; Sanders L; Lang T; Greenwald RA
J Rheumatol; 1998 Aug; 25(8):1472-9. PubMed ID: 9712086
[TBL] [Abstract][Full Text] [Related]
7. Telopeptides as markers of bone turnover in rheumatoid arthritis and osteoarthritis.
Wong PK; Young L; Vaile JH; Tan L; Bertouch JV; Bleasel JF; White C
Intern Med J; 2004; 34(9-10):539-44. PubMed ID: 15482266
[TBL] [Abstract][Full Text] [Related]
8. Measurement of the cross linking compound, pyridinoline, in urine as an index of collagen degradation in joint disease.
Robins SP; Stewart P; Astbury C; Bird HA
Ann Rheum Dis; 1986 Dec; 45(12):969-73. PubMed ID: 3813668
[TBL] [Abstract][Full Text] [Related]
9. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
Papatheofanis FJ
J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144
[TBL] [Abstract][Full Text] [Related]
10. Assessment of urinary hydroxypyridinium cross-links measurement in osteoarthritis.
Graverand MP; Tron AM; Ichou M; Dallard MC; Richard M; Uebelhart D; Vignon E
Br J Rheumatol; 1996 Nov; 35(11):1091-5. PubMed ID: 8948294
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T
Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
[TBL] [Abstract][Full Text] [Related]
12. Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis.
Manicourt DH; Poilvache P; Van Egeren A; Devogelaer JP; Lenz ME; Thonar EJ
Arthritis Rheum; 2000 Feb; 43(2):281-8. PubMed ID: 10693867
[TBL] [Abstract][Full Text] [Related]
13. Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions.
Manicourt DH; Altman RD; Williams JM; Devogelaer JP; Druetz-Van Egeren A; Lenz ME; Pietryla D; Thonar EJ
Arthritis Rheum; 1999 Jun; 42(6):1159-67. PubMed ID: 10366108
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of free and peptide bound collagen crosslink excretion in different skeletal diseases.
Müller A; Jakob K; Hein GE
Ann Rheum Dis; 2003 Jan; 62(1):65-7. PubMed ID: 12480673
[TBL] [Abstract][Full Text] [Related]
15. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
[TBL] [Abstract][Full Text] [Related]
16. Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis.
Martel-Pelletier J; McCollum R; Fujimoto N; Obata K; Cloutier JM; Pelletier JP
Lab Invest; 1994 Jun; 70(6):807-15. PubMed ID: 8015285
[TBL] [Abstract][Full Text] [Related]
17. Short term whole body retention in relation to rate of bone resorption and cartilage degradation after intravenous bisphosphonate (pamidronate) in rheumatoid arthritis.
Cremers SC; Lodder MC; Den Hartigh J; Vermeij P; Van Pelt P; Lems WF; Papapoulos SE; Dijkmans BA
J Rheumatol; 2004 Sep; 31(9):1732-7. PubMed ID: 15338492
[TBL] [Abstract][Full Text] [Related]
18. Hydroxypyridinium collagen crosslinks in serum, urine, synovial fluid and synovial tissue in patients with rheumatoid arthritis compared with osteoarthritis.
Kaufmann J; Mueller A; Voigt A; Carl HD; Gursche A; Zacher J; Stein G; Hein G
Rheumatology (Oxford); 2003 Feb; 42(2):314-20. PubMed ID: 12595629
[TBL] [Abstract][Full Text] [Related]
19. The determination of pyridinium crosslinks in urine and serum as a possible marker of cartilage degradation in rheumatoid arthritis.
Hein G; Franke S; Müller A; Bräunig E; Eidner T; Stein G
Clin Rheumatol; 1997 Mar; 16(2):167-72. PubMed ID: 9093799
[TBL] [Abstract][Full Text] [Related]
20. The effects of sulphasalazine on urinary excretion of the hydroxypyridinium crosslinks of collagen in patients with rheumatoid arthritis.
Dílek K; Alí I; Göksal K; Hüseyin T; Güner T
Yonsei Med J; 2002 Aug; 43(4):435-40. PubMed ID: 12205730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
